207 related articles for article (PubMed ID: 28186725)
1. Small Molecules Engage Hot Spots through Cooperative Binding To Inhibit a Tight Protein-Protein Interaction.
Liu D; Xu D; Liu M; Knabe WE; Yuan C; Zhou D; Huang M; Meroueh SO
Biochemistry; 2017 Mar; 56(12):1768-1784. PubMed ID: 28186725
[TBL] [Abstract][Full Text] [Related]
2. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
[TBL] [Abstract][Full Text] [Related]
3. Mimicking Intermolecular Interactions of Tight Protein-Protein Complexes for Small-Molecule Antagonists.
Xu D; Bum-Erdene K; Si Y; Zhou D; Ghozayel MK; Meroueh SO
ChemMedChem; 2017 Nov; 12(21):1794-1809. PubMed ID: 28960868
[TBL] [Abstract][Full Text] [Related]
4. Small-Molecule Inhibition of the uPAR ⋅ uPA Interaction by Conformational Selection.
Xu D; Bum-Erdene K; Leth JM; Ghozayel MK; Ploug M; Meroueh SO
ChemMedChem; 2021 Jan; 16(2):377-387. PubMed ID: 33107192
[TBL] [Abstract][Full Text] [Related]
5. The effects of amino-acid mutations on specific interactions between urokinase-type plasminogen activator and its receptor: Ab initio molecular orbital calculations.
Tsuji S; Kasumi T; Nagase K; Yoshikawa E; Kobayashi H; Kurita N
J Mol Graph Model; 2011 Aug; 29(8):975-84. PubMed ID: 21605990
[TBL] [Abstract][Full Text] [Related]
6. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
Nagase K; Kobayashi H; Yoshikawa E; Kurita N
J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319
[TBL] [Abstract][Full Text] [Related]
7. Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasion.
Khanna M; Wang F; Jo I; Knabe WE; Wilson SM; Li L; Bum-Erdene K; Li J; W Sledge G; Khanna R; Meroueh SO
ACS Chem Biol; 2011 Nov; 6(11):1232-43. PubMed ID: 21875078
[TBL] [Abstract][Full Text] [Related]
8. Chemical Space Overlap with Critical Protein-Protein Interface Residues in Commercial and Specialized Small-Molecule Libraries.
Si Y; Xu D; Bum-Erdene K; Ghozayel MK; Yang B; Clemons PA; Meroueh SO
ChemMedChem; 2019 Jan; 14(1):119-131. PubMed ID: 30548204
[TBL] [Abstract][Full Text] [Related]
9. The urokinase plasminogen activator binding to its receptor: a quantum biochemistry description within an in/homogeneous dielectric function framework with application to uPA-uPAR peptide inhibitors.
Morais PA; Maia FF; Solis-Calero C; Caetano EWS; Freire VN; Carvalho HF
Phys Chem Chem Phys; 2020 Feb; 22(6):3570-3583. PubMed ID: 31995079
[TBL] [Abstract][Full Text] [Related]
10. A Computational Investigation of Small-Molecule Engagement of Hot Spots at Protein-Protein Interaction Interfaces.
Xu D; Si Y; Meroueh SO
J Chem Inf Model; 2017 Sep; 57(9):2250-2272. PubMed ID: 28766941
[TBL] [Abstract][Full Text] [Related]
11. Ab initio molecular simulations for proposing novel peptide inhibitors blocking the ligand-binding pocket of urokinase receptor.
Mizushima T; Sugimoto T; Kasumi T; Araki K; Kobayashi H; Kurita N
J Mol Model; 2014 Jun; 20(6):2292. PubMed ID: 24859527
[TBL] [Abstract][Full Text] [Related]
12. Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand.
De Souza M; Matthews H; Lee JA; Ranson M; Kelso MJ
Bioorg Med Chem; 2011 Apr; 19(8):2549-56. PubMed ID: 21454081
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of interaction between urokinase-type plasminogen activator and its receptor.
Barinka C; Parry G; Callahan J; Shaw DE; Kuo A; Bdeir K; Cines DB; Mazar A; Lubkowski J
J Mol Biol; 2006 Oct; 363(2):482-95. PubMed ID: 16979660
[TBL] [Abstract][Full Text] [Related]
14. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.
Duriseti S; Goetz DH; Hostetter DR; LeBeau AM; Wei Y; Craik CS
J Biol Chem; 2010 Aug; 285(35):26878-26888. PubMed ID: 20501655
[TBL] [Abstract][Full Text] [Related]
15. Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes.
Kriegbaum MC; Persson M; Haldager L; Alpízar-Alpízar W; Jacobsen B; Gårdsvoll H; Kjær A; Ploug M
Curr Drug Targets; 2011 Nov; 12(12):1711-28. PubMed ID: 21707479
[TBL] [Abstract][Full Text] [Related]
16. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for therapeutic intervention of uPA/uPAR system.
Ngo JC; Jiang L; Lin Z; Yuan C; Chen Z; Zhang X; Yu H; Wang J; Lin L; Huang M
Curr Drug Targets; 2011 Nov; 12(12):1729-43. PubMed ID: 21707478
[TBL] [Abstract][Full Text] [Related]
18. Structural investigations of recombinant urokinase growth factor-like domain.
Beloglazova IB; Beabealashvilli RSh; Gursky YG; Bocharov EV; Mineev KS; Parfenova EV; Tkachuk VA
Biochemistry (Mosc); 2013 May; 78(5):517-30. PubMed ID: 23848154
[TBL] [Abstract][Full Text] [Related]
19. Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor.
Mani T; Liu D; Zhou D; Li L; Knabe WE; Wang F; Oh K; Meroueh SO
ChemMedChem; 2013 Dec; 8(12):1963-77. PubMed ID: 24115356
[TBL] [Abstract][Full Text] [Related]
20. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
